Author

A. E. Jerse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Organism:bacteria (other)· 1 Organism:human· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

K. L. Connolly· 3 shared A. Begum· 1 shared A. E. Sikora· 1 shared A. K. Criss· 1 shared A. Le Van· 1 shared A. Mehrani· 1 shared B. I. Baarda· 1 shared B. Kreiswith· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K. L. Connolly

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Evaluating vaccine-elicited antibody activities against Neisseria gonorrhoeae: cross-protective responses elicited by the 4CMenB meningococcal vaccine

M. C. Gray, K. S. Thomas, E. R. Lamb, L. M. Werner, K. L. Connolly, A. E. Jerse, A. K. Criss

This study evaluates antibody activities against Neisseria gonorrhoeae using assays to assess vaccine efficacy, showing cross-protective responses from the 4CMenB meningococcal vaccine.

bioRxiv · Aug 3, 2023 · PreprintMicrobiology

A novel oral GyrB/ParE dual binding inhibitor effective against multidrug resistant Neisseria gonorrhoeae and other high-threat pathogens

S. Park, R. Russo, L. Westfall, R. Shrestha, M. Zimmerman, V. A. Dartois, N. Kurepina, B. Kreiswith, E. Singleton, S.-G. LI, N. Mittal, Y.-M. Ahn, j. Bilotta, K. L. Connolly, A. E. Jerse, , D. S. Perlin

The paper describes a novel oral inhibitor, JSF-2659, effective against multidrug-resistant Neisseria gonorrhoeae and other high-threat pathogens, with low potential for resistance development.

bioRxiv · Mar 23, 2022Microbiology

A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection

A. E. Sikora, C. Gomez, A. Le Van, B. I. Baarda, s. Darnell, F. G. Martinez, R. A. Zielke, J. A. Bonventre, A. E. Jerse

This study evaluates a gonorrhea vaccine candidate, rMetQ-CpG, showing it induces protective immune responses and accelerates bacterial clearance in a murine model.

bioRxiv · Jun 19, 2020Microbiology

Ribosome rescue inhibitors clear Neisseria gonorrhoeae in vivo using a new mechanism

Z. D. Aron, A. Mehrani, E. D. Hoffer, K. L. Connolly, M. C. Torhan, J. N. Alumasa, P. Srinivas, M. Cabrera, D. Hosangadi, J. S. Barbor, S. C. Cardinale, S. M. Kwasny, L. R. Morin, M. M. Butler, T. J. Opperman, , K. C. Keiler

The paper describes the development of ribosome rescue inhibitors that clear drug-resistant Neisseria gonorrhoeae in vivo through a novel mechanism involving ribosomal conformational changes.

bioRxiv · Jun 4, 2020 · PreprintMicrobiology

Cis- and trans-acting factors influence expression of the norM-encoded efflux pump of Neisseria gonorrhoeae and levels of gonococcal susceptibility to substrate antimicrobials

C. Rouquette-Loughlin, V. Dhulipala, J. L. Reimche, E. Raterman, A. Begum, A. E. Jerse, W. M. Shafer

This study identifies cis- and trans-acting factors regulating the norM efflux pump in Neisseria gonorrhoeae and their impact on antimicrobial susceptibility.

bioRxiv · Apr 25, 2018Microbiology